Scarica l'app Stockscreener
39.36
8.34%
3.03
Dopo l'orario di chiusura:
39.89
0.53
+1.35%
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
Does LENZ Therapeutics Inc. qualify in momentum factor screeningStop Loss & Weekly High Return Opportunities - Newser
LENZ Therapeutics Inc.’s volatility index tracking explainedRate Hike & Verified Chart Pattern Signals - Newser
What the charts say about LENZ Therapeutics Inc. todayJuly 2025 Levels & Risk Managed Investment Signals - Newser
Momentum Screeners Rank LENZ Therapeutics Inc. in Top 5 TodayAI Forecast for Trending Stocks Indicates Upside - beatles.ru
What earnings revisions data tells us about LENZ Therapeutics Inc.Portfolio Safety Metrics and Return Analysis - Newser
What MACD signals say about LENZ Therapeutics Inc.Free Low Risk Picks for Daily Trading - Newser
How to manage a losing position in LENZ Therapeutics Inc.AI Powered Stock Trend Prediction Model - Newser
LENZ Therapeutics Scores Relative Strength Rating Upgrade - Investor's Business Daily
Will LENZ Therapeutics Inc. bounce back from current supportRisk-Managed Swing Setup and Signal Analysis - Newser
LENZ Therapeutics: Evaluate Stock Surge - timothysykes.com
LENZ Therapeutics Soars 11.6% on Explosive Intraday Rally: Technical Breakout or Speculative Surge? - AInvest
LENZ Therapeutics Soars 17.33% on FDA Approval, Strategic Partnership - AInvest
LENZ Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Picks Before News Breakout Reviewed - beatles.ru
Using data models to predict LENZ Therapeutics Inc. stock movementFree Entry Alert With Low Drawdown Strategy - Newser
LENZ Therapeutics Surges 8% — What’s Behind the Intraday Move? - AInvest
Using R and stats models for LENZ Therapeutics Inc. forecastingEarly Entry Ideas with Momentum Potential - Newser
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Nigeria
FDA Approves VIZZ Eye Drops to Treat Presbyopia - Medscape
Lenz Therapeutics price target raised to $53 from $44 at BofA - TipRanks
What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News
When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News
Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News
What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News
What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News
Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World
Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World
Published on: 2025-08-01 19:39:34 - Newser
Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest
Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
LENZ Therapeutics Says FDA Approved Eye Drop to Treat Loss of Near Vision - MarketScreener
Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser
Citigroup maintains Buy rating on LENZ Therapeutics, raises PT to $49. - AInvest
Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):